Abstract. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a multifactorial disease. The pathogenesis of CRSwNP remains unclear. This study was designed to investigate the role of inflammation and Staphylococcus aureus enterotoxin (SE) in this disease. The study included a total of 74 patients with CRSwNP and 6 controls. A serum Phadiatop assay was conducted to detect atopy status, and serum eosinophil cationic protein (ECP) and total immunoglobulin (Ig)E levels were determined using ELISA. SEA, SEB, total IgE, ECP and myeloperoxidase (MPO) levels in nasal tissue supernatant were measured using ELISA. The results indicated that 15 (22.1%) patients had systemic allergies. On the basis of the ECP/MPO ratio, the patients were divided into an eosinophilic CRSwNP group (n=18) and a non-eosinophilic CRSwNP group (n=56). The total ECP/MPO ratio was 0.572, with a notable bias toward neutrophilic inflammation. The supernatant ECP and MPO levels were elevated in the CRSwNP group compared with the control group, but no significant difference in the serum total IgE and ECP levels were observed between the CRSwNP and control groups. In addition, the non-eosinophilic and eosinophilic CRSwNP groups showed significant elevations in supernatant total IgE, SEA and SEB levels compared with the control group. Thus, it may be concluded that allergy is a common pathogenesis of CRSwNP, and neutrophilic inflammation is present in most Chinese CRSwNP patients. Additionally, local indicators reflect the inflammatory status more accurately than do serum indicators. SEs may act as an infection factor rather than as a superantigen in Chinese non-eosinophilic CRSwNP patients. Thus, long-term antibiotic therapy may be an option for Chinese non-eosinophilic CRSwNP patients.

Introduction

Chronic rhinosinusitis (CRS) is a common disease of the nasal cavity and sinuses that affects millions of people worldwide (1). CRS can be divided into two subtypes: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP) (2). Compared with CRSsNP, CRSwNP has a more complex pathogenesis and usually requires surgery (3). At present, the exact origin of CRSwNP remains unclear. Inappropriate therapeutic options lead to a high recurrence rate (4).

According to the type of inflammatory cell infiltration, CRSwNP can be divided into two subgroups: Eosinophilic and non-eosinophilic or neutrophilic (5). Non-eosinophilic CRSwNP always presents with neutrophil-predominant inflammation (6). The subgroups have a variety of pathogeneses and may require different therapeutic options. Eosinophilic subgroup is considered to be induced by Th2 cells, with interleukin (IL)-5 as major cytokine, resulting in increased eosinophil survival and an eosinophilic type of inflammation. The predominant T-effector cell in non-eosinophilic subgroup is the Th17 cell, and resulting in a predominance of neutrophils (7,8). In a previous study, the authors suggested that Caucasian patients with CRSwNP usually manifest with eosinophilic CRSwNP, whereas Chinese patients always show non-eosinophilic inflammation (9). However, this view remains controversial. In the present study, the levels of eosinophil cationic protein (ECP), which is released by active eosinophils, and myeloperoxidase (MPO) were tested to detect the subtype of CRSwNP in Chinese patients.

Staphylococcus aureus and S. aureus enterotoxins (SEs) are common pathogens of CRS. However, the exact underlying pathogenesis remains unclear. SEs are composed mainly of SEA, SEB, SEC, SED and shock syndrome toxin (TSST-1) (10). In Caucasian patients with CRSwNP, SEs have been suggested to act as classic allergens or superantigens, which are able to activate millions of T and B lymphocytes (11). Superantigens elicit the production of high levels of allergen-specific immunoglobulin (Ig)E, and are usually associated with the elevation of total IgE and eosinophilic inflammation (12). However, evidence is lacking concerning the role of superantigens for SEs in Chinese patients with CRSwNP. In non-eosinophilic

Different roles of Staphylococcus aureus enterotoxin in different subtypes of nasal polyps

KE-JIA CHENG, SHEN-QING WANG and YING-YING XU

Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China

Received July 28, 2015; Accepted September 13, 2016

DOI: 10.3892/etm.2016.3951

Correspondence to: Dr Ying-Ying Xu, Department of Otolaryngology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003, P.R. China
E-mail: xuyingying128@163.com

Key words: chronic rhinosinusitis with nasal polyps, superantigen, Staphylococcus aureus enterotoxin, eosinophil cationic protein, myeloperoxidase
CRSwNP, SEs may act as an infection factor; this hypothesis was tested in the current study.

**Materials and methods**

**Subjects.** A total of 74 patients with CRSwNP who had undergone functional endoscopic sinus surgery at the First Affiliated Hospital of the College of Medicine, Zhejiang University (Hangzhou, China) from July to December 2013 (50 males and 24 females; mean age, 42.35 years) were included in the present study. The diagnosis of CRSwNP was based on European Paediatric Ophthalmological Society guidelines (13) and was confirmed by pathological diagnosis after surgery. Patients who used corticosteroids or antihistamines for the previous 4 weeks were excluded from this study, as were patients with asthma. The duration of CRSwNP in the patients ranged from 3 months to 20 years. Six patients who underwent septoplasty or sinus cystectomy were designated as the control group.

The present research was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University. Each patient supplied written informed consent.

**Atopy status detection.** Atopy status was measured in vitro by testing the serum using the Phadiatop test and UniCAP100 automated system (Phadia AB; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's instructions. The test included the most common aeroallergens. The cut-off value was set at 0.35 KU/l.

**Homogenate supernatant of the nasal tissues.** All of the nasal tissues (polyps or turbinates) were collected at the time of surgery, were placed immediately in liquid nitrogen, and then stored at -80°C. Specimens were first thawed in saline (0.1 g in 1 ml) and processed in a tissue homogenizer. The suspensions were then centrifuged for 5 min at 1,006.2 x g. The supernatants were collected and stored at -80°C prior to analysis.

**Total IgE and ECP levels in the serum and supernatant.** Total IgE levels in the serum and nasal tissue supernatant were detected by enzyme-linked immunosorbent assay (#BMS209; ELISA; eBioscience, Vienna, Austria). First, the number of microwell strips required to test the desired number of samples plus the appropriate number of wells needed to run the blanks and standards were determined. Each sample, standard, blank and optional control sample was assayed in duplicate. Next, horseradish peroxidase (HRP)-conjugated antibody was prepared. The microwell strips were washed twice with ~400 µl Wash Buffer per well with thorough aspiration of the microwell contents between washes. Then, 100 µl Assay Buffer (1X) was added in duplicate to the blank wells, followed by the addition of 90 µl Assay Buffer (1X) and 10 µl each sample in duplicate to the sample wells. To each well, including the blank wells, 50 µl diluted HRP-conjugated antibody was then added. The wells were covered with an adhesive film and incubated at room temperature (18-25°C) for 30 min, taking care to avoid direct exposure to intense light. The enzyme reaction was stopped by quickly pipetting 100 µl Stop Solution into each well. The absorbance of each microwell was read on a spectrophotometer using 450 nm as the primary wavelength, and the results were calculated.

ECP levels were also measured by ELISA (#SK00128-01; Aviscera Bioscience, Inc., Santa Clara, CA, USA), according to the manufacturer protocol.

**SEA, SEB and MPO levels in the supernatant.** SEA [#BIO(TW)-E01(Hu)-00254] and SEB [#BIO(TW)-E01(Hu)-00253] levels were measured using ELISA (R&D Systems, Inc., Minneapolis, MN, USA). MPO levels were also detected using an ELISA kit (#BMS2038INST; eBioscience) according to the manufacturer's protocol.

**Results**

**Atopy status of CRSwNP patients.** Serum testing was conducted for 68 CRSwNP patients and 6 controls. Among the CRSwNP patients 15 (22.1%) showed positive results in the Phadiatop test, and none of the controls exhibited atopy.

**ECP and MPO levels in nasal tissue supernatant.** All of the CRSwNP patients and controls underwent the supernatant tests. As described previously, eosinophilic CRSwNP is characterized by a supernatant ECP/MPO ratio >2 (14). According to this criterion, 18 patients were assigned to an eosinophilic CRSwNP group, and the others were assigned to the non-eosinophilic CRSwNP group. The total ECP/MPO ratio was 0.572, with a notable bias toward neutrophilic inflammation. Table I lists the ECP and MPO levels in the supernatants of the three groups. The supernatant ECP level was significantly elevated in the non-eosinophilic and eosinophilic CRSwNP groups compared with that in the control group (P<0.022 and P<0.001, respectively). The supernatant MPO level was significantly elevated in the non-eosinophilic CRSwNP group compared with the control group (P=0.001) (Fig. 1).

**Total IgE and ECP levels in the serum.** In the CRSwNP group, the ECP level in the serum was 10.55 µg/l (range, 6.92-22.60 µg/l). Compared with the control group, the CRSwNP group, including eosinophilic and non-eosinophilic subgroups, showed no significant elevation in serum ECP level. In the CRSwNP group, the total IgE level in the serum was 45.70 KU/l (20.00-152.75 KU/l). Compared with the control group, the CRSwNP group showed no significant difference in the serum total IgE level. Data are listed in Table II and Fig. 2.

**Total IgE and SE levels in the supernatant.** Table III summarizes total IgE and SE levels in the supernatant. Compared
with the control group, the non-eosinophilic and eosinophilic CRSwNP groups showed significant elevations in supernatant total IgE levels (P=0.013 and P<0.001, respectively). The eosinophilic CRSwNP group also showed a significant elevation in supernatant total IgE level compared with that in the non-eosinophilic group (P<0.001). Compared with the control group, the non-eosinophilic and eosinophilic CRSwNP groups showed significant elevations in the supernatant SEA levels (P=0.006 and P=0.04, respectively) and SEB levels (P=0.001 and P=0.004, respectively). The differences in supernatant SEA and SEB levels between the non-eosinophilic and eosinophilic CRSwNP groups were not found to be statistically significant (Fig. 3).

Discussion

CRSwNP is a complex disease that presents challenges to rhinologists. Its pathogenesis remains unclear, with allergy, infection, inflammation, anatomic abnormality, bacterial superantigen and biofilm being suggested (15). The recurrence rate for CRSwNP is high after surgery or drug treatment in certain patients (16). In the past, allergy was considered to be an important pathogenesis of CRSwNP (17). Allergic CRSwNP showed a worse therapeutic response than non-allergic CRSwNP in patients treated with budesonide nasal spray (18). However, its underlying pathogenesis remains unclear (19). In the present study, 15 (22.1%) CRSwNP patients showed atopy, representing a higher incidence than that for healthy people. This finding suggests that atopy remains a common pathogenesis of CRSwNP, a viewpoint that is shared with two previous studies (20,21).

Previously, CRSwNP was regarded as being associated with T helper (Th)2-predominant inflammation, with increased eosinophil infiltration and IgE elevation (22). In the present study, the serum total IgE and ECP levels were not observed to be increased in the CRSwNP groups compared with those

Table I. ECP and MPO levels in the nasal tissue supernatant.

<table>
<thead>
<tr>
<th>Group</th>
<th>ECP (µg/l)</th>
<th>P-value</th>
<th>MPO (µg/l)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-eosinophilic CRSwNP</td>
<td>36.31 (20.70-69.15)</td>
<td>0.022</td>
<td>72.64 (34.65-178.37)</td>
<td>0.001</td>
</tr>
<tr>
<td>Eosinophilic CRSwNP</td>
<td>121.38 (63.59-164.57)</td>
<td>&lt;0.001</td>
<td>26.09 (18.14-49.57)</td>
<td>0.820</td>
</tr>
<tr>
<td>Control</td>
<td>15.00 (13.21-31.32)</td>
<td></td>
<td>27.34 (14.92-30.26)</td>
<td></td>
</tr>
</tbody>
</table>

ECP, eosinophil cationic protein; MPO, myeloperoxidase; CRSwNP, chronic rhinosinusitis with nasal polyps.

Table II. Serum total IgE and ECP level in different groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>Serum total IgE (KU/l)</th>
<th>P-value</th>
<th>Serum ECP (µg/l)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRSwNP</td>
<td>45.70 (20.00-152.75)</td>
<td>0.945</td>
<td>10.55 (6.92-22.60)</td>
<td>0.494</td>
</tr>
<tr>
<td>Non-eosinophilic CRSwNP</td>
<td>42.65 (19.88-140.75)</td>
<td>0.990</td>
<td>9.49 (6.18-17.28)</td>
<td>0.291</td>
</tr>
<tr>
<td>Eosinophilic CRSwNP</td>
<td>79.65 (24.90-194.00)</td>
<td>0.820</td>
<td>14.45 (9.80-42.80)</td>
<td>0.673</td>
</tr>
<tr>
<td>Control</td>
<td>46.80 (17.08-296.75)</td>
<td></td>
<td>13.85 (9.56-26.58)</td>
<td></td>
</tr>
</tbody>
</table>

IgE, immunoglobulin E; ECP, eosinophil cationic protein; CRSwNP, chronic rhinosinusitis with nasal polyps.

Figure 1. ECP and MPO levels in nasal tissue supernatants. (A) The supernatant ECP level was significantly elevated in the non-eosinophilic and eosinophilic CRSwNP groups compared with that in the control group. (B) The supernatant MPO level was significantly elevated in the non-eosinophilic CRSwNP group and was also elevated in the eosinophilic CRSwNP group, albeit not significantly so. ECP, eosinophil cationic protein; MPO, myeloperoxidase; CRSwNP, chronic rhinosinusitis with nasal polyps.
in the control group. It is thus suggested that these indicators in local tissues or nasal lavage might be more sensitive than those in the serum.

Currently, CRSwNP is subdivided into two subgroups: Eosinophilic and non-eosinophilic. Different CRS endotypes

<table>
<thead>
<tr>
<th>Group</th>
<th>Total IgE (KU/l)</th>
<th>P-value</th>
<th>SEA (µg/l)</th>
<th>P-value</th>
<th>SEB (µg/l)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-eosinophilic CRSwNP</td>
<td>22.72 (9.22-36.22)</td>
<td>0.013^a</td>
<td>77.99 (43.00-132.45)</td>
<td>0.006^a</td>
<td>9.85 (4.73-17.04)</td>
<td>0.001^a</td>
</tr>
<tr>
<td>Eosinophilic CRSwNP</td>
<td>50.15 (34.28-90.74)</td>
<td>&lt;0.001^b</td>
<td>71.56 (29.82-109.21)</td>
<td>0.541^b</td>
<td>10.97 (5.00-27.99)</td>
<td>0.597^b</td>
</tr>
<tr>
<td>Control</td>
<td>7.71 (5.25-8.79)</td>
<td>&lt;0.001^c</td>
<td>27.38 (12.58-53.41)</td>
<td>0.04^c</td>
<td>3.28 (1.23-5.13)</td>
<td>0.004^c</td>
</tr>
</tbody>
</table>

^aNon-eosinophilic CRSwNP group vs. control group, ^bnon-eosinophilic CRSwNP group vs. eosinophilic CRSwNP group, ^ceosinophilic CRSwNP group vs. control group. IgE, immunoglobulin E; SEA, *Staphylococcus aureus* enterotoxin A; SEB, *S. aureus* enterotoxin B; CRSwNP, chronic rhinosinusitis with nasal polyps.

Figure 2. Total IgE and ECP levels in the serum. (A) The CRSwNP group showed no significant difference in serum total IgE level compared with the control group. (B) The CRSwNP group, including the eosinophilic and non-eosinophilic groups, showed no significant elevation in serum ECP level. CRSwNP, chronic rhinosinusitis with nasal polyps; IgE, immunoglobulin E; ECP, eosinophil cationic protein.

Figure 3. Total IgE and SE levels in nasal tissue supernatant. (A) Compared with the control, the non-eosinophilic and eosinophilic CRSwNP groups showed significant increases in supernatant total IgE levels. The eosinophilic CRSwNP group also showed a significant elevation in supernatant total IgE level compared with that in the non-eosinophilic group. Compared with the control, the non-eosinophilic and eosinophilic CRSwNP groups showed significant elevations in supernatant (B) SEA and (C) SEB levels. CRSwNP, chronic rhinosinusitis with nasal polyps; IgE, immunoglobulin E; SEA, *Staphylococcus aureus* enterotoxin A; SEB, *S. aureus* enterotoxin B.
The study was supported by Zhejiang Province Public Welfare Funds (grant no. 2014C33203).

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/LMh1RB.

References